NADAC acquisition cost data for GENOTROPIN 5 MG CARTRIDGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
| 00013262681 | $678.53 | 2022-01-01 | Rx |
Generic: Somatropin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $17.9M | 7,472 | 1,046 | $327.71 |
| 2020 | $18.3M | 7,564 | 1,077 | $527.17 |
| 2021 | $22.2M | 9,719 | 1,225 | $517.70 |
| 2022 | $23.9M | 10,147 | 1,257 | $510.84 |
| 2023 | $27.2M | 12,020 | 1,572 | $511.64 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $4.3M | 1,747 | 218 |
| Texas | $2.0M | 828 | 115 |
| Florida | $1.6M | 691 | 90 |
| Massachusetts | $1.2M | 605 | 83 |
| Ohio | $1.2M | 488 | 62 |
| New York | $1.2M | 474 | 64 |
| Michigan | $1.1M | 589 | 75 |
| Washington | $1.1M | 508 | 64 |
| Pennsylvania | $1.1M | 457 | 74 |
| Arizona | $1.0M | 478 | 66 |
| Oregon | $914.5K | 391 | 48 |
| Georgia | $874.6K | 472 | 66 |
| Indiana | $865.6K | 341 | 45 |
| Minnesota | $756.7K | 348 | 44 |
| Illinois | $637.4K | 185 | 22 |
| North Carolina | $608.7K | 237 | 37 |
| Virginia | $598.0K | 270 | 38 |
| Tennessee | $570.5K | 296 | 38 |
| Nevada | $538.9K | 222 | 31 |
| Oklahoma | $516.8K | 235 | 28 |
| Wisconsin | $405.9K | 192 | 26 |
| Kansas | $401.6K | 219 | 24 |
| Missouri | $384.5K | 162 | 20 |
| New Jersey | $325.4K | 99 | 16 |
| Alabama | $309.4K | 159 | 19 |
| Colorado | $254.0K | 121 | 18 |
| West Virginia | $244.0K | 134 | 15 |
| Kentucky | $195.0K | 111 | 18 |
| Arkansas | $185.8K | 44 | N/A |
| Maryland | $184.2K | 112 | 16 |
| Louisiana | $164.6K | 76 | 13 |
| Connecticut | $158.2K | 69 | 13 |
| Idaho | $149.5K | 75 | 11 |
| Nebraska | $138.9K | 30 | N/A |
| Maine | $135.7K | 56 | N/A |
| Mississippi | $124.8K | 48 | N/A |
| New Mexico | $122.6K | 62 | N/A |
| Utah | $112.5K | 36 | N/A |
| New Hampshire | $108.6K | 78 | N/A |
| Puerto Rico | $102.1K | 45 | N/A |
| South Carolina | $63.3K | 37 | N/A |
| District of Columbia | $58.8K | 20 | N/A |
| Iowa | $58.3K | 47 | N/A |
| South Dakota | $57.0K | 35 | N/A |
| Montana | $51.6K | 21 | N/A |
| Vermont | $46.3K | 29 | N/A |
| Rhode Island | $41.8K | 12 | N/A |
| Hawaii | $18.2K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.